/CNTB

CNTB Stock - Connect Biopharma Holdings Limited

Q: What is the analyst price target for CNTB?

Analyst price target information is not currently available for CNTB.

Q: What is CNTB's market cap?

Market capitalization information is not currently available for CNTB.

Healthcare|Biotechnology|NASDAQ

$2.27-1.30%

$0.03 (-1.30%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

High Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

100

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+296.5%upside

Target: $9.00

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for CNTB

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta-0.18

52W High$3.28

52W Low$0.51

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$26.03M	N/A	N/A	N/A	N/A
Gross Profit	$26.03M	$-988,000	$-1,030,634	N/A	N/A
Gross Margin	100.0%	N/A	N/A	N/A	N/A
Operating Income	$-22,452,000	$-62,074,000	$-117,661,644	$-99,151,869	$-30,295,313
Net Income	$-15,628,000	$-59,503,000	$-116,415,196	$-205,205,345	$-120,303,936
Net Margin	-60.0%	N/A	N/A	N/A	N/A
EPS	$-0.28	$-1.08	$-14.50	$-25.00	$-14.45

Company Overview

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation. The company was founded in 2012 and is headquartered in Taicang, China.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

100%

Hold / Neutral

Sell / Underperform

Analyst Consensus🟢 Bullish

4 Bullish0 Neutral/Bearish

Price Targets

Average Target

↑ 263.4% Upside

Now

Low

Average

$10

High

Based on 4 analysts

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
December 1st 2025	Lake Street	Initiation	Buy	$9
October 31st 2025	BTIG Research	Initiation	Buy	$10
June 12th 2025	H.C. Wainwright	Initiation	Buy	$7
March 4th 2024	H.C. Wainwright	Initiation	Buy	$7

Earnings History & Surprises

CNTB

Beat Rate

78%

Last 9 quarters

Avg Surprise

+64.2%

EPS vs Estimate

Beats / Misses

7/2

Last 12 quarters

Latest EPS

$-0.23

Q3 2025

EPS Surprise History

Q1 22

+96.2%

$-0.17vs$-4.38

Q3 22

+96.9%

$-0.16vs$-5.28

Q2 23

+95.8%

$-0.15vs$-3.58

Q3 23

+98.9%

$-0.08vs$-6.92

Q2 24

-131.7%

$-0.07vs$-0.03

Q3 24

+167.5%

$0.02vs$-0.03

Q1 25

+78.7%

$-0.06vs$-0.27

Q3 25

-4.5%

$-0.23vs$-0.22

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q1 2026	Mar 30, 2026	$-0.30	—	—	—
Q3 2025	Aug 13, 2025	$-0.22	$-0.23	-4.5%	✗ MISS
Q1 2025	Mar 31, 2025	$-0.27	$-0.06	+78.7%	✓ BEAT
Q3 2024	Sep 5, 2024	$-0.03	$0.02	+167.5%	✓ BEAT
Q2 2024	Apr 16, 2024	$-0.03	$-0.07	-131.7%	✗ MISS
Q3 2023	Sep 12, 2023	$-6.92	$-0.08	+98.9%	✓ BEAT
Q2 2023	Apr 11, 2023	$-3.58	$-0.15	+95.8%	✓ BEAT
Q3 2022	Sep 13, 2022	$-5.28	$-0.16	+96.9%	✓ BEAT
Q1 2022	Mar 31, 2022	$-4.38	$-0.17	+96.2%	✓ BEAT
Q3 2021	Aug 31, 2021	$-2.36	$-0.48	+79.7%	✓ BEAT
Q1 2021	Mar 19, 2021	—	$-0.00	—	—
Q2 2020	Jun 30, 2020	—	$-0.00	—	—
Q4 2019	Dec 31, 2019	—	$-0.03	—	—
Q2 2019	Jun 30, 2019	—	$-0.03	—	—

Frequently Asked Questions about CNTB

What is CNTB's current stock price?

Connect Biopharma Holdings Limited (CNTB) is currently trading at $2.27 per share. The stock has moved -1.30% today.

What is the analyst price target for CNTB?

The average analyst price target for CNTB is $9.00, based on 1 analyst.

What sector is Connect Biopharma Holdings Limited in?

Connect Biopharma Holdings Limited operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is CNTB's market cap?

Connect Biopharma Holdings Limited has a market capitalization of $0.13 billion, making it a small-cap company.

Does CNTB pay dividends?

No, Connect Biopharma Holdings Limited does not currently pay a dividend to shareholders.